Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime®) in Rio de Janeiro, Brazil

Revista do Instituto de Medicina Tropical de Sao Paulo

Volumn 42, Issue 6, 2000, Pages 321-325

  De Oliveira Neto, M P ^a   Mattos, M ^a   Pirmez, C ^a   Fernandes, O ^a   Goncalves Costa S C ^a   De Souza, C D F S ^a   Grimaldi G , Jr ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Antimony; Leishmania (Viannia) braziliensis; Mucosal leishmaniasis; Therapy

Indexed keywords

MEGLUMINE ANTIMONATE;

ADULT; AGED; ARTICLE; ASTHENIA; BRAZIL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHILIA; FEMALE; HEART ARRHYTHMIA; HUMAN; INJECTION PAIN; LARYNX; LEISHMANIASIS; LEUKOPENIA; MALE; MAXILLARY SINUS; NAUSEA; NOSE MUCOSA; PALATE; PHARYNX; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; VOMITING;

EID: 0034522755     PISSN: 00364665     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-46652000000600004     Document Type: Article

References (36)

1. Electrocardiographic alterations during treatment of mucocutaneous leishmaniasis with meglumine antimoniate and allopurinol
2. Acute renal failure in visceral leishmaniasis treated with sodium stibogluconate
3. Leishmaniasis
4. Genetic diversity in natural populations of New World Leishmania
5. A revised classification for Leishmania and Endotrypanum
6. Clinical healing of antimony-resistant cutaneous or mucocutaneous leishmaniasis following the combined administration of interferon-gamma and pentavalent antimonial compounds
7. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis
8. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis
9. Leishmaniasis
10. A review of the geographic distribution and epidemiology of leishmaniasis in the New World
11. Leishmaniases of the New World: Current concepts and implications for future research
12. Leishmania ssp.: Development of pentostan-resistant clones in vitro by discontinuous drug exposure
13. Drug resistance in leishmaniasis: Its implication in systemic chemotherapy of cutaneous and mucocutaneous disease
14. Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis
15. Hepatotoxicity of sodium stibogluconate in leishmaniasis
16. Leishmaniasis
17. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies
18. Renal tubular acidosis, a side effect of treatment with pentavalent antimony
19. Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis
20. Mucosal leishmaniasis ("Espundia", Escomel, 1911)
21. Mucocutaneous leishmaniasis
22. Mucosal leishmaniasis due to Leishmania (Viannia) braziliensis L(V)b in Três Braços, Bahia-Brazil
23. Clinical observations of unresponsive mucosal leishmaniasis
24. Human mucocutaneous leishmaniasis in Três Braços, Bahia, Brasil. An area of Leishmania braziliensis braziliensis transmission. III. Mucosal disease presentation and initial evolution
25. Padronização do antígeno de Montenegro
26. Mucosal leishmniasis unresponsive to glucantime therapy successfully treated with AmBisome
27. v) in American cutaneous leishmaniasis. A five-years follow-up study of 15 patients
28. A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: Extensive follow-up studies (up to 10) years
29. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil - An area of Leishmania (V.) braziliensis transmission
30. Treatment of American cutaneous leishmaniasis: A comparison between low dosage (5mg/kg/day) and high dosage (20mg/kg/day) antimony regimens
31. Use of PCR in diagnosis of human American tegumentary leishmaniasis in Rio de Janeiro, Brazil
32. Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis
33. Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis
34. Racial differences in espundia
35. The Leishmaniasis